Literature DB >> 29794010

Neuromyelitis optica spectrum disorder presenting as rhomboencephalitis.

Maria Stavrou1,2,3, Lucy Francis2,4, Nomathamsanqa Tshuma5, Klaus Schmierer2,3.   

Abstract

Rhomboencephalitis, at least in its acute phase, is often a severely disabling syndrome, and can be life threatening. A range of underlying conditions can lead to this clinical syndrome. Rapid diagnosis to initiate treatment early is key to a beneficial outcome. We report the case of a 22 year old Afro-Caribbean woman, who presented with a two -week history of walking difficulties, upper limb incoordination and slurred speech. Her brainstem function deteriorated at pace, and she developed hypersomnia. A broad diagnostic approach led to prophylactic treatment for the most common infectious causes. This did not improve her symptoms. Non-infectious inflammatory causes were therefore considered and plasma exchange treatment was initiated leading to marked improvement within days. Screening for autoimmune conditions confirmed aquaporin-4 positive neuromyelitis optica spectrum disorder (NMOSD) as the underlying cause. Immunotherapy with rituximab was started. So far, no relapse has been observed. While the definition of NMOSD continues to be refined, aquaporin-4 testing should be considered early in patients presenting with rhomboencephalitis who do not respond to antibiotic and antiviral treatment. Vigilance and early intervention are key to limit morbidity and mortality from NMOSD. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  brain stem / cerebellum; multiple sclerosis; neuroimaging; neurological injury; neurology

Mesh:

Substances:

Year:  2018        PMID: 29794010      PMCID: PMC5976129          DOI: 10.1136/bcr-2017-222255

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  13 in total

1.  The clinical course of neuromyelitis optica (Devic's syndrome).

Authors:  D M Wingerchuk; W F Hogancamp; P C O'Brien; B G Weinshenker
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

2.  Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab.

Authors:  H L Pellkofer; M Krumbholz; A Berthele; B Hemmer; L A Gerdes; J Havla; R Bittner; M Canis; E Meinl; R Hohlfeld; T Kuempfel
Journal:  Neurology       Date:  2011-04-12       Impact factor: 9.910

3.  Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study.

Authors:  M Cohen; G Romero; J Bas; M Ticchioni; M Rosenthal; R Lacroix; C Brunet; A Rico; J Pelletier; B Audoin; C Lebrun
Journal:  J Neurol Sci       Date:  2017-01-10       Impact factor: 3.181

4.  Neuromyelitis optica treatment: analysis of 36 patients.

Authors:  Denis Bernardi Bichuetti; Enedina Maria Lobato de Oliveira; Daniel May Oliveira; Nilton Amorin de Souza; Alberto Alain Gabbai
Journal:  Arch Neurol       Date:  2010-09

5.  Brain involvement in neuromyelitis optica spectrum disorders.

Authors:  Koon Ho Chan; C T Tse; C P Chung; Raymand L C Lee; J S C Kwan; P W L Ho; J W M Ho
Journal:  Arch Neurol       Date:  2011-11

6.  Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability.

Authors:  Hélène Zéphir; Raphaël Bernard-Valnet; Christine Lebrun; Olivier Outteryck; Bertrand Audoin; Bertrand Bourre; Sophie Pittion; Sandrine Wiertlewski; Jean Christophe Ouallet; Jean-Philippe Neau; Jonathan Ciron; Pierre Clavelou; Romain Marignier; David Brassat
Journal:  J Neurol       Date:  2015-07-21       Impact factor: 4.849

7.  Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients.

Authors:  Liene Elsone; Jay Panicker; Kerry Mutch; Mike Boggild; Richard Appleton; Anu Jacob
Journal:  Mult Scler       Date:  2013-08-28       Impact factor: 6.312

8.  Aquaporins and brain edema.

Authors:  Donald E G Griesdale; Christopher R Honey
Journal:  Surg Neurol       Date:  2004-05

9.  Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.

Authors:  Anu Jacob; Brian G Weinshenker; Ivo Violich; Nancy McLinskey; Lauren Krupp; Robert J Fox; Dean M Wingerchuk; Mike Boggild; Cris S Constantinescu; Aaron Miller; Tracy De Angelis; Marcelo Matiello; Bruce A C Cree
Journal:  Arch Neurol       Date:  2008-09-08

10.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.

Authors:  Dean M Wingerchuk; Brenda Banwell; Jeffrey L Bennett; Philippe Cabre; William Carroll; Tanuja Chitnis; Jérôme de Seze; Kazuo Fujihara; Benjamin Greenberg; Anu Jacob; Sven Jarius; Marco Lana-Peixoto; Michael Levy; Jack H Simon; Silvia Tenembaum; Anthony L Traboulsee; Patrick Waters; Kay E Wellik; Brian G Weinshenker
Journal:  Neurology       Date:  2015-06-19       Impact factor: 9.910

View more
  1 in total

1.  Autoimmune rhomboencephalitis: A pediatric case report.

Authors:  Achille Marino; Francesco Canonico; Raffaella Maria Pinzani; Massimo Andreotti; Tiziana Varisco; Alberto Maria Cappellari
Journal:  Turk Pediatri Ars       Date:  2020-12-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.